title: Effects on growth after switching protease inhibitors to efavirenz in HIV-1-infected children.
authors.forename: Raffaella
authors.initials: R
authors.lastname: Rosso
authors.forename: Antonio
authors.initials: A
authors.lastname: Di Biagio
authors.forename: Chiara
authors.initials: C
authors.lastname: Dentone
authors.forename: Matteo
authors.initials: M
authors.lastname: Bassetti
authors.forename: Claudio
authors.initials: C
authors.lastname: Viscoli
authors.forename: Arianna
authors.initials: A
authors.lastname: Parodi
authors.forename: Andrea
authors.initials: A
authors.lastname: De Maria
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D000293:Adolescent; D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D048588:Benzoxazines; D002648:Child; D003521:Cyclopropanes; D005260:Female; D006128:Growth / Q000187:drug effects*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1; D006801:Humans; D008297:Male; D010078:Oxazines / Q000627:therapeutic use*
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D010078:Oxazines; C098320:efavirenz